CFTR Activity Is Enhanced by the Novel Corrector GLPG2222, Given With and Without Ivacaftor in Two Randomized Trials

Journal of Cystic Fibrosis - Netherlands
doi 10.1016/j.jcf.2019.04.014
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Adaptive Pre-Specification in Randomized Trials With and Without Pair-Matching

Statistics in Medicine
EpidemiologyStatisticsProbability
2016English

Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2017English

Low Free Drug Concentration Prevents Inhibition of F508del CFTR Functional Expression by the Potentiator VX-770 (Ivacaftor)

British Journal of Pharmacology
Pharmacology
2016English

Group Homogeneity Is Paramount in Randomized Trials

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2019English

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype

Clinical Pharmacology and Therapeutics
Pharmacology
2014English

Human PrimPol Activity Is Enhanced by RPA

Scientific Reports
Multidisciplinary
2017English

Discovery of a Picomolar Potency Pharmacological Corrector of the Mutant CFTR Chloride Channel

Science advances
Multidisciplinary
2020English

The Magnitude of Ivacaftor Effects on Fluid Secretion via R117h-CFTR Channels: Human in Vivo Measurements

PLoS ONE
Multidisciplinary
2017English

Insulin Secretion Improves in Cystic Fibrosis Following Ivacaftor Correction of CFTR: A Small Pilot Study

Pediatric Diabetes
Internal MedicinePediatricsEndocrinologyPerinatologyChild HealthMetabolismDiabetes
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy